Charlene Dobashi
Nurse Practitioner · Temecula, CANPI 1477193977
Payments from drug & device makers
Across 189 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Amgen$937
- Xeris Pharmaceuticals, Inc.$290
- AbbVie$243
- Corcept Therapeutics$230
- Lilly USA, LLC$221
- plus $1K from 22 others
What the payments were for
- Travel & lodging$60913%
- Food & beverage$3,86785%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 20 | $1,239 |
| Amgen(2 entities) | 43 | $937 |
| Xeris Pharmaceuticals, Inc. | 18 | $290 |
| AbbVie(2 entities) | 17 | $243 |
| Corcept Therapeutics | 12 | $230 |
| Lilly USA, LLC | 17 | $221 |
| Bayer | 4 | $195 |
| Pfizer | 9 | $175 |
| Tandem Diabetes Care, Inc. | 10 | $140 |
| Ascensia Diabetes Care US Inc. | 7 | $134 |
| Insulet Corporation | 2 | $133 |
| Mannkind Corporation | 5 | $131 |
| Johnson & Johnson | 4 | $71 |
| Biohaven Pharmaceuticals, Inc. | 2 | $47 |
| AstraZeneca | 3 | $42 |
| Astellas Pharma US Inc | 2 | $37 |
| Merck | 2 | $31 |
| Sanofi | 1 | $29 |
| GSK | 2 | $29 |
| Dexcom, Inc. | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| Boehringer Ingelheim | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Novartis | 1 | $20 |
| BETA Bionics, Inc. | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Cequr Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$840
- TEPEZZA$359
- Kerendia$124
- Omnipod$106
How this compares
$4,535 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 154 | $193,139 |
| TrulicityDulaglutide | 139 | $181,118 |
| JardianceEmpagliflozin | 118 | $139,586 |
| MounjaroTirzepatide | 82 | $113,743 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $82,162 |
| FarxigaDapagliflozin Propanediol | 66 | $65,336 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $38,224 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $32,160 |
| RybelsusSemaglutide | 27 | $31,125 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $20,999 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 46 | $19,673 |
| JanuviaSitagliptin Phosphate | 18 | $17,577 |
| Repatha SureclickEvolocumab | 23 | $17,510 |
| Novolog FlexpenInsulin Aspart | 43 | $17,017 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $16,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $221 | $306,123252 claims |
| Boehringer IngelheimJardiance, Tradjenta | $24 | $153,789134 claims |
| AstraZenecaFarxiga | $42 | $65,33666 claims |
| MerckJanuvia | $31 | $17,57718 claims |
| Johnson & JohnsonInvokana | $71 | $9,89811 claims |
| Sanofi-aventis U.S. LLCLantus | $27 | $3,65712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Temecula
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.